As of 2025-05-04, the EV/EBITDA ratio of Bridge Biotherapeutics Inc (288330.KQ) is -1.28. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. 288330.KQ's latest enterprise value is 32,510.38 mil KRW. 288330.KQ's TTM EBITDA according to its financial statements is -25,458.73 mil KRW. Dividing these 2 quantities gives us the above 288330.KQ EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 10.5x - 18.7x | 14.6x |
| Forward P/E multiples | 12.3x - 20.6x | 16.4x |
| Fair Price | (5,751.02) - (8,844.91) | (7,305.28) |
| Upside | -743.3% - -1089.4% | -917.1% |
| Date | EV/EBITDA |
| 2025-05-02 | -1.24 |
| 2025-04-30 | -1.28 |
| 2025-04-29 | -1.63 |
| 2025-04-28 | -1.67 |
| 2025-04-25 | -1.78 |
| 2025-04-24 | -1.86 |
| 2025-04-23 | -2.02 |
| 2025-04-22 | -2.04 |
| 2025-04-21 | -2.55 |
| 2025-04-18 | -3.87 |
| 2025-04-17 | -5.76 |
| 2025-04-16 | -8.46 |
| 2025-04-15 | -12.31 |
| 2025-04-14 | -17.81 |
| 2025-04-11 | -17.79 |
| 2025-04-10 | -15.86 |
| 2025-04-09 | -14.88 |
| 2025-04-08 | -15.84 |
| 2025-04-07 | -15.14 |
| 2025-04-04 | -14.83 |
| 2025-04-03 | -15.29 |
| 2025-04-02 | -15.29 |
| 2025-04-01 | -15.22 |
| 2025-03-31 | -15.43 |
| 2025-03-28 | -15.84 |
| 2025-03-27 | -16.31 |
| 2025-03-26 | -14.77 |
| 2025-03-25 | -14.20 |
| 2025-03-24 | -14.77 |
| 2025-03-21 | -11.90 |
| 2025-03-20 | -11.95 |
| 2025-03-19 | -12.46 |
| 2025-03-18 | -12.91 |
| 2025-03-17 | -12.91 |
| 2025-03-14 | -12.91 |
| 2025-03-13 | -12.15 |
| 2025-03-12 | -11.99 |
| 2025-03-11 | -10.94 |
| 2025-03-10 | -9.71 |
| 2025-03-07 | -9.75 |
| 2025-03-06 | -9.68 |
| 2025-03-05 | -9.61 |
| 2025-03-04 | -9.39 |
| 2025-02-28 | -9.32 |
| 2025-02-27 | -9.69 |
| 2025-02-26 | -9.06 |
| 2025-02-25 | -8.87 |
| 2025-02-24 | -9.11 |
| 2025-02-21 | -9.73 |
| 2025-02-20 | -8.52 |